Trials / Completed
CompletedNCT04388813
Predictors of Severe COVID-19 Outcomes
Predictors of Severe COVID-19 Outcomes (PRESCO)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 494 (actual)
- Sponsor
- Verily Life Sciences LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Conditions
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2021-09-23
- Completion
- 2021-09-23
- First posted
- 2020-05-14
- Last updated
- 2024-05-28
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04388813. Inclusion in this directory is not an endorsement.